Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: No Debt )
KPTI' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.96
KPTI's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 0.96 )
KPTI' s 10-Year Equity to Asset Range
Min: -21.26   Max: 0.98
Current: 0.96

-21.26
0.98
Interest Coverage No Debt
KPTI's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: No Debt )
KPTI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 113.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -24238.97
KPTI's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: -24238.97 )
KPTI' s 10-Year Operating margin (%) Range
Min: -8772.61   Max: -2506.31
Current: -24238.97

-8772.61
-2506.31
Net-margin (%) -24221.60
KPTI's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: -24221.60 )
KPTI' s 10-Year Net-margin (%) Range
Min: -8771.83   Max: -2505.99
Current: -24221.6

-8771.83
-2505.99
ROE (%) -58.25
KPTI's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: -58.25 )
KPTI' s 10-Year ROE (%) Range
Min: -53.44   Max: -53.44
Current: -58.25

ROA (%) -45.77
KPTI's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: -45.77 )
KPTI' s 10-Year ROA (%) Range
Min: -372.3   Max: -42.56
Current: -45.77

-372.3
-42.56
ROC (Joel Greenblatt) (%) -15457.78
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: -15457.78 )
KPTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11975.31   Max: -9718.65
Current: -15457.78

-11975.31
-9718.65
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

KPTI Guru Trades in

Q4 2013

KPTI Guru Trades in Q4 2013

Steven Cohen 9,624 sh (New)
» More
Q1 2014

KPTI Guru Trades in Q1 2014

Steven Cohen Sold Out
» More
Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Karyopharm Therapeutics Inc.

Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Inc. and Nimble Storage Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Karopharm Therapeuticcs Inc, Methode Electronics Inc, Gilead Sciences Inc, and Nimble Storage Inc. Read more...

Ratios

vs
industry
vs
history
P/B 7.60
KPTI's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 7.60 )
KPTI' s 10-Year P/B Range
Min: 5.2   Max: 9.74
Current: 7.6

5.2
9.74
EV-to-EBIT -19.70
KPTI's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: -19.70 )
KPTI' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -19.7

Current Ratio 23.96
KPTI's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 23.96 )
KPTI' s 10-Year Current Ratio Range
Min: 0.49   Max: 47.98
Current: 23.96

0.49
47.98
Quick Ratio 23.96
KPTI's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 23.96 )
KPTI' s 10-Year Quick Ratio Range
Min: 0.49   Max: 47.98
Current: 23.96

0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.60
KPTI's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 7.60 )
KPTI' s 10-Year Price/Net Cash Range
Min: 4.47   Max: 10.72
Current: 7.6

4.47
10.72
Price/Net Current Asset Value 7.60
KPTI's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 7.60 )
KPTI' s 10-Year Price/Net Current Asset Value Range
Min: 4.47   Max: 10.72
Current: 7.6

4.47
10.72
Price/Tangible Book 7.30
KPTI's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 7.30 )
KPTI' s 10-Year Price/Tangible Book Range
Min: 4.4   Max: 10.28
Current: 7.3

4.4
10.28
Price/Median PS Value 0.90
KPTI's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KPTI: 0.90 )
KPTI' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 0.85
Current: 0.9

0.75
0.85

Business Description

Industry: »
Compare: » details
Traded in other countries:25K.Germany
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Our Partners
Stocks Continue Lower On Merger Monday Sep 29 2014 - BENZINGA

More From Other Websites
8:05 am Karyopharm Therapeutics announces Clinical Data for Selinexor (KPT-330) in advanced solid... Sep 29 2014
Karyopharm Announces Clinical Data For Selinexor (KPT-330) In Advanced Solid Tumors Sep 29 2014
Karyopharm Announces Clinical Data for Selinexor (KPT-330) in Advanced Solid Tumors Sep 29 2014
3 Unusual-Volume Biotech Stocks in Breakout Territory Sep 29 2014
Karyopharm Therapeutics, Inc. (KPTI) Surges: Stock Adds 10.5% Sep 29 2014
Karyopharm to Host Conference Call to Discuss Selinexor (KPT-330) Data Presented at ESMO 2014 Sep 25 2014
Karyopharm Announces Three Clinical Data Presentations at ESMO 2014 Sep 09 2014
KARYOPHARM THERAPEUTICS INC. Financials Aug 15 2014
CFO Moves: Karyopharm, Education Realty Trust Aug 08 2014
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Aug 08 2014
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer Aug 08 2014
Karyopharm to Present at the Wedbush 2014 Life Sciences Management Access Conference Aug 07 2014
Q2 2014 Karyopharm Therapeutics Inc Earnings Release - Time Not Supplied Aug 07 2014
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Karyopharm Therapeutics Reports Second Quarter Financial Results for 2014 Aug 07 2014
Karyopharm to Host Second Quarter 2014 Earnings Call on August 7, 2014 Aug 01 2014
Karyopharm Theraputics: Will It Be An EPIX Fail? Jul 22 2014
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc. ... Jul 06 2014
Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% Jul 02 2014
Karyopharm files to sell 2.2M shares of common stock Jun 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK